Literature DB >> 11696844

Group B streptococcal neonatal infections in Rio Grande do Sul, Brazil.

E Miura1, M C Martin.   

Abstract

UNLABELLED: Group B Streptococcus is the most common pathogen found in neonatal sepsis in North America.
OBJECTIVES: We describe 15 cases of neonatal infections by Group B Streptococcus (Streptococcus agalactiae) at a Neonatal Intensive Care Unit of a public and teaching hospital.
METHODS: We conducted a study at Hospital de Clínicas de Porto Alegre, from January 1st, 1996 to June 30, 1999. Diagnosis of neonatal infection was established according to the findings of Group B Streptococcus in blood culture associated with alterations resembling sepsis on the basis of clinical picture and laboratory findings.
RESULTS: Fifteen cases of neonatal infections by Group B Streptococcus were detected. Eleven cases consisted of early-onset sepsis, 2 cases of occult bacteremia and 2 cases of late-onset sepsis. Eight cases had septic shock (53%), 8 cases had pneumonia (53%), and 4 cases had meningitis (27%). Fourteen cases were diagnosed from a positive blood culture, and 1 case from evidence of these bacteria in pulmonary anatomopathological examination. Thirteen cases (87%) were diagnosed before 72 hours of life. We had 3 deaths (20%), and 3 cases of meningitis developing neurological deficits.
CONCLUSIONS: Streptococcus Group B is one of the most important pathogens in the etiology of early-onset neonatal sepsis at our hospital, with high mortality and morbidity. However, we do not know the incidence of GBS neonatal infections at other hospitals. More data are needed to establish a basis for trials of different strategies to reduce these infections.

Entities:  

Mesh:

Year:  2001        PMID: 11696844     DOI: 10.1590/s0036-46652001000500001

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  7 in total

1.  Antibiotic prescribing practices in paediatric septic shock in a tertiary care hospital in a resource limited setting: an audit.

Authors:  Varsha Vekaria-Hirani; Rashmi Kumar; Rachel Musoke
Journal:  Pan Afr Med J       Date:  2019-11-07

Review 2.  Early-Onset Neonatal Sepsis in Low- and Middle-Income Countries: Current Challenges and Future Opportunities.

Authors:  Kirsty Sands; Owen B Spiller; Kathryn Thomson; Edward A R Portal; Kenneth C Iregbu; Timothy R Walsh
Journal:  Infect Drug Resist       Date:  2022-03-09       Impact factor: 4.003

3.  A combined enrichment/polymerase chain reaction based method for the routine screening of Streptococcus agalactiae in pregnant women.

Authors:  F M Munari; F De-Paris; G D Salton; P S Lora; P Giovanella; A B M P Machado; L S Laybauer; K R P Oliveira; C Ferri; J L S Silveira; C C F C Laurino; R M Xavier; A L Barth; S Echeverrigaray; J P Laurino
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

4.  Emerging trends in invasive and noninvasive isolates of Streptococcus agalactiae in a Latin American hospital: a 17-year study.

Authors:  Maria del Pilar Crespo-Ortiz; Claudia Rocio Castañeda-Ramirez; Monica Recalde-Bolaños; Juan Diego Vélez-Londoño
Journal:  BMC Infect Dis       Date:  2014-08-03       Impact factor: 3.090

5.  Group B streptococcus neonatal infection in an intensive care unit in Brazil: high fatality and missed opportunities for antibiotic prophylaxis.

Authors:  Marilia Lopes Bahia Evangelista; Felipe Teixeira de Mello Freitas
Journal:  Braz J Infect Dis       Date:  2014-08-29       Impact factor: 3.257

6.  Assessment of conventional PCR and real-time PCR compared to the gold standard method for screening Streptococcus agalactiae in pregnant women.

Authors:  Michele Berger Ferreira; Fernanda de-Paris; Rodrigo Minuto Paiva; Luciana de Souza Nunes
Journal:  Braz J Infect Dis       Date:  2018-11-22       Impact factor: 3.257

7.  Early-onset neonatal sepsis and the implementation of group B streptococcus prophylaxis in a Brazilian maternity hospital: a descriptive study.

Authors:  Felipe Teixeira de Mello Freitas; Gustavo Adolfo Sierra Romero
Journal:  Braz J Infect Dis       Date:  2016-11-19       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.